Trial Profile
A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Azilsartan (Primary) ; Telmisartan
- Indications Essential hypertension; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Takeda
- 26 Jul 2016 Status changed from active, no longer recruiting to completed.
- 07 Apr 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 11 Feb 2016 Planned number of patients changed from 100 to 40, according to ClinicalTrials.gov record.